Gilead Sciences (BUE:GILD) Cyclically Adjusted Book per Share: ARS7,595.05 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:GILD Gilead Sciences Inc BUE:GILD
60 GF Score
Price ARS60,025.00
GF Value ARS42,530.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Gilead Sciences Cyclically Adjusted Book per Share?

Gilead Sciences BUE:GILD +1.01% 60 Cyclically Adjusted Book per Share is ARS7,595.05 as of Jun. 2026. GuruFocus rates BUE:GILD with a GF Score™ of 60/100 and a GF Value™ of ARS42,530.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share for the three months ended in Jun. 2026 was ARS14,117.381. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS7,595.05 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Book Growth Rate was 3.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 8.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Gilead Sciences was 29.80% per year. The lowest was 2.40% per year. And the median was 23.40% per year.

As of today (2026-09-04), Gilead Sciences's current stock price is ARS60025.00. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was ARS7,595.05. Gilead Sciences's Cyclically Adjusted PB Ratio of today is 7.90.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 14.20. The lowest was 3.56. And the median was 5.95.


Gilead Sciences  (BUE:GILD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=60025.00/7595.05
=7.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 14.20. The lowest was 3.56. And the median was 5.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Gilead Sciences Cyclically Adjusted Book per Share Related Terms


Gilead Sciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cyclically Adjusted Book per Share Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 733.78 1,372.09 4,307.38 5,406.43 7,215.69

Gilead Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,678.72 7,316.19 7,215.69 7,140.65 7,595.05

BUE:GILD vs PFE, BMY, AMGN: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.


BUE:GILD
60GF Score
Gilead Sciences Inc BUE:GILD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14117.381/333.9520*333.9520
=14,117.381

Current CPI (Jun. 2026) = 333.9520.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 190.330 241.428 263.271
201612 228.554 241.432 316.139
201703 241.116 243.801 330.274
201706 286.293 244.955 390.309
201709 333.107 246.819 450.702
201712 298.425 246.524 404.259
201803 319.145 249.554 427.078
201806 417.052 251.989 552.704
201809 650.125 252.439 860.052
201812 629.015 251.233 836.120
201903 673.520 254.202 884.821
201906 797.865 256.143 1,040.234
201909 910.189 256.759 1,183.832
201912 1,063.507 256.974 1,382.086
202003 1,092.251 258.115 1,413.166
202006 984.153 257.797 1,274.879
202009 1,033.613 260.280 1,326.176
202012 1,181.243 260.474 1,514.464
202103 1,361.400 264.877 1,716.428
202106 1,488.409 271.696 1,829.461
202109 1,672.778 274.310 2,036.483
202112 1,696.777 278.802 2,032.418
202203 1,704.863 287.504 1,980.294
202206 1,941.785 296.311 2,188.454
202209 2,335.889 296.808 2,628.214
202212 2,855.562 296.797 3,213.040
202303 3,323.684 301.836 3,677.331
202306 4,071.917 305.109 4,456.849
202309 6,261.776 307.789 6,794.046
202312 6,615.117 306.746 7,201.827
202403 11,850.020 312.332 12,670.293
202406 13,140.102 314.175 13,967.258
202409 14,092.726 315.301 14,926.353
202412 15,665.436 315.605 16,576.112
202503 16,407.550 319.799 17,133.681
202506 18,807.418 322.561 19,471.588
202509 23,552.003 324.800 24,215.636
202512 26,559.389 324.054 27,370.627
202603 26,473.215 330.213 26,772.971
202606 14,117.381 333.952 14,117.381

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ARS7,595.05 mean?
Gilead Sciences (BUE:GILD) has a Cyclically Adjusted Book per Share of ARS7,595.05 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Cyclically Adjusted Book per Share too high?
Gilead Sciences' current Cyclically Adjusted Book per Share is ARS7,595.05. Overall, Gilead Sciences has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Cyclically Adjusted Book per Share compare to PFE and BMY?
Gilead Sciences' Cyclically Adjusted Book per Share of ARS7,595.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Cyclically Adjusted Book per Share is ARS7,595.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (BUE:GILD) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS42,530.57, compared to a current price of ARS60,025.00 — trading 41.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is ARS7,595.05. Gilead Sciences' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Gilead Sciences (BUE:GILD), the current Cyclically Adjusted Book per Share is ARS7,595.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (BUE:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of ARS60,025.00 is trading 41.1% above its estimated GF Value™ of ARS42,530.57. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for BUE:GILD:

  • Cyclically Adjusted Book per Share: ARS7,595.05
  • GF Value™: ARS42,530.57 vs. price of ARS60,025.00 (41.1% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the BUE:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
60GF Score

Get the complete analysis for BUE:GILD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS60,025.00
Price
ARS42,530.57
GF Value